[Leukaemomycin-blocked mutants of Streptomyces griseus and their pigments. III. 11-Desoxydaunomycinone derivatives from the mutant ZIMET 43699/G44]

[Biosynthesis of anthracycline: a new interpretation of the results for daunomycin biosynthesis]

On the basis of literature data and our own experiments the "late" biosynthetic pathway to daunomycin has been interpreted from a new point of view considering both the in vivo biosynthesis and formation of shunt products. In contrast to existing hypotheses proposed by other authors we discuss a modified sequence leading to C-11 oxidation and, as a consequence, understand epsilon-rhodomycinone as a shunt product instead of a biosynthetic intermediate. In addition, a new hypothesis about the "early" steps of the ring formation from polyketides by a sequence of enzyme reactions has been proposed.

Advances in bioconversion of anthracycline antibiotics

During the last decade new anthracycline-type structures with potential usefulness in cancer treatment have been supplied both by new microbial strains and by bioconversions of precursor molecules employing cells or enzymes. We highlight recent advances in bioconversion of anthracycline structures with the main focus on late transformations such as are carried out by oxidoreductases.